

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bountra, et al. 9 October 2007
Appln. No.: 10/540,100 Group Art Unit: 1609
Filed: June 20, 2005 Examiner: Jean-Louis, Samira, JM
For: VR-1/COX-2 COMBINATION CASE

RESPONSE TO RESTRICTION REQUIREMENT


Sir:

This paper is filed in response to the Restriction Requirement mailed October 3, 2007. Claims 1-12 are pending in the application.

Applicants select Group I claims. Additionally, Applicants elect *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea as the VR-1 agonist and rofecoxib as the NSAID. In this case, the NSAID is also the COX-2 inhibitor.

Authorization is hereby granted to charge any fees which may be required by this paper to Deposit Account No. 19-2570.

Respectfully submitted,



Reid S. Willis
Agent for Applicants
Registration No. 39,429

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7481
Facsimile (610) 270-5090